Niels Christian Foldager Sandgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Niels Christian Foldager Sandgaard has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Arne Johannessen
Department of Cardiology Copenhagen University Hospital Gentofte Hellerup Denmark
2 shared publications - Henning Bundgaard
Copenhagen University Hospital
2 shared publications - Henrik Kjærulf Jensen
Aarhus University Hospital
2 shared publications - Jens Brock Johansen
Department of Cardiology, Odense University Hospital , Odense
2 shared publications - Morten Salling Olesen
Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Peter Karl Jacobsen
The Heart Centre, Rigshospitalet , Copenhagen
2 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2393-2402
A Comparison of Safety and Outcome Using Three Different Sedation Strategies During Pulsed Field Ablation for Atrial Fibrillation
Background: Pulsed field ablation (PFA) is an emerging modality for atrial fibrillation (AF) ablation. However, adequate sedation of patients during treatment is imperative. Objective: Our aim was to compare safety and outcome after deep sedation (DS) managed by electrophysiology staff (EP‐DS), DS by an anaesthesia nurse (AN‐DS), and general anaesthesia (GA) during PFA AF ablation. Methods: All Danish patients undergoing first‐time AF ablation with pentaspline PFA technique from 2021 to 2024 were included. Patients were stratified according to sedation strategy. EP‐DS and AN‐DS were defined as sedation without assisted ventilation managed by EP staff and an anaesthesia nurse, respectively. Patients in GA underwent endotracheal intubation and were monitored by anaesthesia staff. Patient selection for the sedation strategy was based on the institutional practice. Results: Of 1269 patients, 661 (52%) underwent EP‐DS, 173 (14%) underwent AN‐DS, and 435 (34%) underwent GA. Overall, sedation complications were few, and no procedures were abandoned due to adverse effects of sedation. In the EP‐DS group, the anaesthesiologist was unexpectedly called for back‐up in 1 (0.2%) patient due to prolonged hypotension during the procedure. In the AN‐DS group, the anaesthesiologist was called due to desaturation in 1 patient (0.6%) but without the need for escalation to intubation. In the GA group, no periprocedural sedation complications occurred. We found no difference in 1‐year atrial tachycardia recurrence between sedation groups. Conclusion: In this nationwide cohort, EP staff‐administered deep sedation was feasible and associated with few clinically significant sedation‐related adverse events during PFA. No significant differences in observed atrial tachyarrhythmia recurrence rates were identified between sedation strategies.
- 27 September 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2393-2402
Open AccessA Comparison of Safety and Outcome Using Three Different Sedation Strategies During Pulsed Field Ablation for Atrial Fibrillation
Background: Pulsed field ablation (PFA) is an emerging modality for atrial fibrillation (AF) ablation. However, adequate sedation of patients during treatment is imperative. Objective: Our aim was to compare safety and outcome after deep sedation (DS) managed by electrophysiology staff (EP‐DS), DS by an anaesthesia nurse (AN‐DS), and general anaesthesia (GA) during PFA AF ablation. Methods: All Danish patients undergoing first‐time AF ablation with pentaspline PFA technique from 2021 to 2024 were included. Patients were stratified according to sedation strategy. EP‐DS and AN‐DS were defined as sedation without assisted ventilation managed by EP staff and an anaesthesia nurse, respectively. Patients in GA underwent endotracheal intubation and were monitored by anaesthesia staff. Patient selection for the sedation strategy was based on the institutional practice. Results: Of 1269 patients, 661 (52%) underwent EP‐DS, 173 (14%) underwent AN‐DS, and 435 (34%) underwent GA. Overall, sedation complications were few, and no procedures were abandoned due to adverse effects of sedation. In the EP‐DS group, the anaesthesiologist was unexpectedly called for back‐up in 1 (0.2%) patient due to prolonged hypotension during the procedure. In the AN‐DS group, the anaesthesiologist was called due to desaturation in 1 patient (0.6%) but without the need for escalation to intubation. In the GA group, no periprocedural sedation complications occurred. We found no difference in 1‐year atrial tachycardia recurrence between sedation groups. Conclusion: In this nationwide cohort, EP staff‐administered deep sedation was feasible and associated with few clinically significant sedation‐related adverse events during PFA. No significant differences in observed atrial tachyarrhythmia recurrence rates were identified between sedation strategies.
- Open Access
- 7 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (10)
Early substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial
Aims: Ventricular tachyarrhythmias (VT/VF) are common among patients with prior myocardial infarction (MI). MANTRA-VT trial was designed to compare the efficacy and safety of early substrate-based radiofrequency catheter ablation (RFCA) to antiarrhythmic drug (AAD) therapy for ventricular tachyarrhythmias. Methods and results: We randomly assigned 58 AAD naïve post MI patients with implantable cardioverter defibrillator (ICD) and at least one documented VT/VF episode after the device implantation to an initial treatment strategy of substrate-based RFCA or AAD therapy. The primary endpoint was cumulative number of ventricular tachyarrhythmias (VT/VF burden) at 12 months. The secondary endpoints included all-cause mortality, hospitalization, adverse events, and VT/VF burden at 24 months. Analyses were performed on an intention-to-treat basis. The median number of VT/VF episodes at 12 months was zero in both the RFCA (range 0–3) and the AAD group (range 0–23) (P = 0.454), whereas the rate of appropriate ICD shocks was 7% and 30% in the RFCA and the AAD groups (P = 0.026), respectively. During the extended follow-up, 82% of the patients in the RFCA group and 63% in the AAD group had no ICD therapies (P = 0.012). There was no significant difference between the groups in total mortality (HR 1.02, 95% CI 0.20–5.11, P = 0.86) and hospitalization (HR 1.35, 95% CI 0.36–5.09. P = 0.66) at 24 months. Therapy-related adverse events occurred in 3.6% and 16.7% of the patients in the RFCA and the AAD groups (P = 0.10), respectively. Conclusion: Early substrate-based RFCA was associated with reduced risk of ICD therapies, but with no meaningful difference in VT/VF burden, mortality, hospitalization, and adverse events.
- 7 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (10)
Open AccessEarly substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial
Aims: Ventricular tachyarrhythmias (VT/VF) are common among patients with prior myocardial infarction (MI). MANTRA-VT trial was designed to compare the efficacy and safety of early substrate-based radiofrequency catheter ablation (RFCA) to antiarrhythmic drug (AAD) therapy for ventricular tachyarrhythmias. Methods and results: We randomly assigned 58 AAD naïve post MI patients with implantable cardioverter defibrillator (ICD) and at least one documented VT/VF episode after the device implantation to an initial treatment strategy of substrate-based RFCA or AAD therapy. The primary endpoint was cumulative number of ventricular tachyarrhythmias (VT/VF burden) at 12 months. The secondary endpoints included all-cause mortality, hospitalization, adverse events, and VT/VF burden at 24 months. Analyses were performed on an intention-to-treat basis. The median number of VT/VF episodes at 12 months was zero in both the RFCA (range 0–3) and the AAD group (range 0–23) (P = 0.454), whereas the rate of appropriate ICD shocks was 7% and 30% in the RFCA and the AAD groups (P = 0.026), respectively. During the extended follow-up, 82% of the patients in the RFCA group and 63% in the AAD group had no ICD therapies (P = 0.012). There was no significant difference between the groups in total mortality (HR 1.02, 95% CI 0.20–5.11, P = 0.86) and hospitalization (HR 1.35, 95% CI 0.36–5.09. P = 0.66) at 24 months. Therapy-related adverse events occurred in 3.6% and 16.7% of the patients in the RFCA and the AAD groups (P = 0.10), respectively. Conclusion: Early substrate-based RFCA was associated with reduced risk of ICD therapies, but with no meaningful difference in VT/VF burden, mortality, hospitalization, and adverse events.
- Open Access
- 25 June 2025
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 1687-1693
First in-human results of the MAGiC robotic magnetic navigation radiofrequency ablation catheter
Robotic magnetic navigation (RMN) has demonstrated clinical utility in treating arrhythmia patients by providing direct distal-tip control of an ablation catheter, enhancing catheter precision, safety, and stability with an atraumatic catheter design. We aimed to assess the first in-human efficacy and safety of the new RMN-guided MAGiCTM radiofrequency ablation catheter. This prospective, multicenter single-arm, unblinded study enrolled 67 patients with arrhythmias that met EHRA guidelines for catheter ablation. All patients were treated for their index arrhythmia with the MAGiC RMN catheter. All other devices used in the procedures were approved for treatment including a RMN System (Genesis/Niobe®) used to navigate the MAGiC catheter. Acute procedural success and adverse events were assessed for all patients through discharge from the hospital in the days following the procedure. Sixty-seven patients were treated as follows: 25 cases of atrioventricular nodal reentrant tachycardia, 19 of premature ventricular contractions, 8 of Wolf-Parkinson-White (WPW) syndrome, 8 of atrial fibrillation, 3 of atrial flutter, and 4 of ventricular tachycardia. Acute procedural success was 94%. There was one cardiac tamponade due to perforation of the right ventricular outflow tract during ablation. Otherwise, no adverse events were observed. The results of this study demonstrate good acute efficacy and safety of the MAGiC RMN ablation catheter independent of underlying arrhythmias. Contact force and stability with MAGiC seem improved compared to previous catheters available with RMN, and therefore radiofrequency energy delivery needs careful attention, especially in thin areas of the myocardium. Additional long-term data are needed.
- 25 June 2025
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 1687-1693
Open AccessFirst in-human results of the MAGiC robotic magnetic navigation radiofrequency ablation catheter
Robotic magnetic navigation (RMN) has demonstrated clinical utility in treating arrhythmia patients by providing direct distal-tip control of an ablation catheter, enhancing catheter precision, safety, and stability with an atraumatic catheter design. We aimed to assess the first in-human efficacy and safety of the new RMN-guided MAGiCTM radiofrequency ablation catheter. This prospective, multicenter single-arm, unblinded study enrolled 67 patients with arrhythmias that met EHRA guidelines for catheter ablation. All patients were treated for their index arrhythmia with the MAGiC RMN catheter. All other devices used in the procedures were approved for treatment including a RMN System (Genesis/Niobe®) used to navigate the MAGiC catheter. Acute procedural success and adverse events were assessed for all patients through discharge from the hospital in the days following the procedure. Sixty-seven patients were treated as follows: 25 cases of atrioventricular nodal reentrant tachycardia, 19 of premature ventricular contractions, 8 of Wolf-Parkinson-White (WPW) syndrome, 8 of atrial fibrillation, 3 of atrial flutter, and 4 of ventricular tachycardia. Acute procedural success was 94%. There was one cardiac tamponade due to perforation of the right ventricular outflow tract during ablation. Otherwise, no adverse events were observed. The results of this study demonstrate good acute efficacy and safety of the MAGiC RMN ablation catheter independent of underlying arrhythmias. Contact force and stability with MAGiC seem improved compared to previous catheters available with RMN, and therefore radiofrequency energy delivery needs careful attention, especially in thin areas of the myocardium. Additional long-term data are needed.
- 28 October 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (10) , 862-865
Genetic Variants Close to TTN , NKX2-5 , and MYH6 Associate With AVNRT
- 28 October 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (10) , 862-865
Genetic Variants Close to TTN , NKX2-5 , and MYH6 Associate With AVNRT
- Open Access
- 20 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (47) , 4946-4956
Risk factors for cardiac implantable electronic device infections: a nationwide Danish study
Cardiac implantable electronic device (CIED) infection is a severe complication to modern management of cardiac arrhythmias. The CIED type and the type of surgery are recognized as risk factors for CIED infections, but knowledge of patient-related risk factors is scarce. This study aimed to identify lifelong patient-related risk factors for CIED infections. Consecutive Danish patients undergoing a CIED implantation or reoperation between January 1996 and April 2018 were included. The cohort consisted of 84 429 patients undergoing 108 494 CIED surgeries with a combined follow-up of 458 257 CIED-years. A total of 1556 CIED explantations were classified as either pocket (n = 1022) or systemic CIED infection (n = 534). Data were cross-linked with records from the Danish National Patient Registry and the Danish National Prescription Registry. Using multiple-record and multiple-event per subject proportional hazard analysis, specific patient-related risk factors were identified but with several variations amongst the subtypes of CIED infection. CIED reoperations were associated with the highest risk of pocket CIED infection but also CIED type, young age, and prior valvular surgery [hazard ratio (HR): 1.62, 95% confidence interval (CI): 1.29–2.04]. Severe renal insufficiency/dialysis (HR: 2.40, 95% CI: 1.65–3.49), dermatitis (HR: 2.80, 95% CI: 1.92–4.05), and prior valvular surgery (HR: 2.09, 95% CI: 1.59–2.75) were associated with the highest risk of systemic CIED infections. Congestive heart failure, ischaemic heart disease, malignancy, chronic obstructive pulmonary disease, and temporary pacing were not significant at multivariate analysis. Specific comorbidities and surgical procedures were associated with a higher risk of CIED infections but with variations amongst pocket and systemic CIED infection. Pocket CIED infections were associated with CIED reoperations, young age and more complex type of CIED, whereas systemic CIED infections were associated with risk factors predisposing to bacteraemia.
- 20 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (47) , 4946-4956
Open AccessRisk factors for cardiac implantable electronic device infections: a nationwide Danish study
Cardiac implantable electronic device (CIED) infection is a severe complication to modern management of cardiac arrhythmias. The CIED type and the type of surgery are recognized as risk factors for CIED infections, but knowledge of patient-related risk factors is scarce. This study aimed to identify lifelong patient-related risk factors for CIED infections. Consecutive Danish patients undergoing a CIED implantation or reoperation between January 1996 and April 2018 were included. The cohort consisted of 84 429 patients undergoing 108 494 CIED surgeries with a combined follow-up of 458 257 CIED-years. A total of 1556 CIED explantations were classified as either pocket (n = 1022) or systemic CIED infection (n = 534). Data were cross-linked with records from the Danish National Patient Registry and the Danish National Prescription Registry. Using multiple-record and multiple-event per subject proportional hazard analysis, specific patient-related risk factors were identified but with several variations amongst the subtypes of CIED infection. CIED reoperations were associated with the highest risk of pocket CIED infection but also CIED type, young age, and prior valvular surgery [hazard ratio (HR): 1.62, 95% confidence interval (CI): 1.29–2.04]. Severe renal insufficiency/dialysis (HR: 2.40, 95% CI: 1.65–3.49), dermatitis (HR: 2.80, 95% CI: 1.92–4.05), and prior valvular surgery (HR: 2.09, 95% CI: 1.59–2.75) were associated with the highest risk of systemic CIED infections. Congestive heart failure, ischaemic heart disease, malignancy, chronic obstructive pulmonary disease, and temporary pacing were not significant at multivariate analysis. Specific comorbidities and surgical procedures were associated with a higher risk of CIED infections but with variations amongst pocket and systemic CIED infection. Pocket CIED infections were associated with CIED reoperations, young age and more complex type of CIED, whereas systemic CIED infections were associated with risk factors predisposing to bacteraemia.
- 1 April 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (4) , 231-240
Electrocardiographic Findings, Arrhythmias, and Left Ventricular Involvement in Familial ST-Depression Syndrome
Background: Familial ST-depression syndrome is an inherited disease characterized by persistent, nonischemic ST-deviations, and risk of arrhythmias and heart failure. We aimed at further characterizing the ECG, arrhythmias, and structural characteristics associated with this novel syndrome. Methods: Retrospective analysis of data from consecutive families with familial ST-depression Syndrome in Denmark. ECG features, prevalence and type of arrhythmias, occurrence of systolic dysfunction, and medium-term outcome were analyzed. Results: Forty affected individuals (43% men; mean age at diagnosis 49.1 years) from 14 apparently unrelated families with ≥2 affected members were included. Autosomal dominant inheritance was observed in all families. The ECG phenotype seemed to develop in prepuberty and the ST-deviations were persistent and most pronounced in leads V4/V5/II, respectively. Serial ECG analyses showed stable to slow progression of the ECG phenotype. Exercise accentuated the ST-deviations with a maximum difference between rest/stress (mean) of −117 μV in lead V5. During a mean follow-up of 9.3±7.1 years 5 (13%) patients developed sustained ventricular arrhythmias or (aborted) sudden cardiac death, 10 (25%) developed atrial fibrillation, 2 (5%) other supraventricular arrhythmias, and 10 (25%) were diagnosed with left ventricular ejection fraction ≤50%. The ventricular arrhythmias were polymorphic with relatively short-coupled premature ventricular contractions at onset (300–360 ms); no QT prolongation was observed. Seven patients had at least one catheter ablation; 5 for supraventricular arrhythmias and 2 for ventricular arrhythmias. Males experienced more arrhythmic end points than females ( P <0.01). Conclusions: The familial ST-depression ECG phenotype is stable to slowly progressive after medium-term follow-up. Clinically, both supra- and ventricular arrhythmias are common; as are some degree of left ventricular systolic dysfunction. Familial ST-depression represent a novel inherited cause of polymorphic ventricular tachycardia.
- 1 April 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (4) , 231-240
Electrocardiographic Findings, Arrhythmias, and Left Ventricular Involvement in Familial ST-Depression Syndrome
Background: Familial ST-depression syndrome is an inherited disease characterized by persistent, nonischemic ST-deviations, and risk of arrhythmias and heart failure. We aimed at further characterizing the ECG, arrhythmias, and structural characteristics associated with this novel syndrome. Methods: Retrospective analysis of data from consecutive families with familial ST-depression Syndrome in Denmark. ECG features, prevalence and type of arrhythmias, occurrence of systolic dysfunction, and medium-term outcome were analyzed. Results: Forty affected individuals (43% men; mean age at diagnosis 49.1 years) from 14 apparently unrelated families with ≥2 affected members were included. Autosomal dominant inheritance was observed in all families. The ECG phenotype seemed to develop in prepuberty and the ST-deviations were persistent and most pronounced in leads V4/V5/II, respectively. Serial ECG analyses showed stable to slow progression of the ECG phenotype. Exercise accentuated the ST-deviations with a maximum difference between rest/stress (mean) of −117 μV in lead V5. During a mean follow-up of 9.3±7.1 years 5 (13%) patients developed sustained ventricular arrhythmias or (aborted) sudden cardiac death, 10 (25%) developed atrial fibrillation, 2 (5%) other supraventricular arrhythmias, and 10 (25%) were diagnosed with left ventricular ejection fraction ≤50%. The ventricular arrhythmias were polymorphic with relatively short-coupled premature ventricular contractions at onset (300–360 ms); no QT prolongation was observed. Seven patients had at least one catheter ablation; 5 for supraventricular arrhythmias and 2 for ventricular arrhythmias. Males experienced more arrhythmic end points than females ( P <0.01). Conclusions: The familial ST-depression ECG phenotype is stable to slowly progressive after medium-term follow-up. Clinically, both supra- and ventricular arrhythmias are common; as are some degree of left ventricular systolic dysfunction. Familial ST-depression represent a novel inherited cause of polymorphic ventricular tachycardia.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Cardiovascular Imaging
- Vol. 30 (1) , 62-75
Mitral Annulus Calcification and Cardiac Conduction Disturbances: A DANCAVAS Sub-study
Rasmussen JH, et al. J Cardiovasc Imaging. 2022 Jan;30(1):62-75. https://doi.org/10.4250/jcvi.2021.0110
- 1 January 2022
- Published by XMLink in Journal of Cardiovascular Imaging
- Vol. 30 (1) , 62-75
Open AccessMitral Annulus Calcification and Cardiac Conduction Disturbances: A DANCAVAS Sub-study
Rasmussen JH, et al. J Cardiovasc Imaging. 2022 Jan;30(1):62-75. https://doi.org/10.4250/jcvi.2021.0110
- 1 November 2003
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 285 (5) , R971-R980
Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs
Evidence of biological activity of fragments of ANG II is accumulating. Fragments considered being inactive degradation products might mediate actions previously attributed to ANG II. The study aimed to determine whether angiotensin fragments exert biological activity when administered in amounts equimolar to physiological doses of ANG II. Cardiovascular, endocrine, and renal effects of ANG II, ANG III, ANG IV, and ANG-(1-7) (6 pmol·kg-1·min-1) were investigated in conscious dogs during acute inhibition of angiotensin I-converting enzyme (enalaprilate) and aldosterone (canrenoate). Furthermore, ANG III was investigated by step-up infusion (30 and 150 pmol·kg-1·min-1). Arterial plasma concentrations [ANG immunoreactivity (IR)] were determined by an ANG II antibody cross-reacting with ANG III and ANG IV. Metabolic clearance rates were higher for ANG III and ANG IV (391 ± 19 and 274 ± 13 ml·kg-1·min-1, respectively) than for ANG II (107 ± 13 ml·kg-1·min-1). ANG II increased ANG IR by 60 ± 7 pmol/ml, blood pressure by 30%, increased plasma aldosterone markedly (to 345 ± 72 pg/ml), and plasma vasopressin transiently, while reducing glomerular filtration rate (40 ± 2 to 33 ± 2 ml/min), sodium excretion (50 ± 7 to 16 ± 4 μmol/min), and urine flow. Equimolar amounts of ANG III induced similar antinatriuresis (57 ± 8 to 19 ± 3 μmol/min) and aldosterone secretion (to 268 ± 71 pg/ml) at much lower ANG IR increments (∼1/7) without affecting blood pressure, vasopressin, or glomerular filtration rate. The effects of ANG III exhibited complex dose-response relations. ANG IV and ANG-(1-7) were ineffective. It is concluded that 1) plasma clearances of ANG III and ANG IV are higher than those of ANG II; 2) ANG III is more potent than ANG II in eliciting immediate sodium and potassium retention, as well as aldosterone secretion, particularly at low concentrations; and 3) the complexity of the ANG III dose-response relationships provides indirect evidence that several effector mechanisms are involved.
- 1 November 2003
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 285 (5) , R971-R980
Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs
Evidence of biological activity of fragments of ANG II is accumulating. Fragments considered being inactive degradation products might mediate actions previously attributed to ANG II. The study aimed to determine whether angiotensin fragments exert biological activity when administered in amounts equimolar to physiological doses of ANG II. Cardiovascular, endocrine, and renal effects of ANG II, ANG III, ANG IV, and ANG-(1-7) (6 pmol·kg-1·min-1) were investigated in conscious dogs during acute inhibition of angiotensin I-converting enzyme (enalaprilate) and aldosterone (canrenoate). Furthermore, ANG III was investigated by step-up infusion (30 and 150 pmol·kg-1·min-1). Arterial plasma concentrations [ANG immunoreactivity (IR)] were determined by an ANG II antibody cross-reacting with ANG III and ANG IV. Metabolic clearance rates were higher for ANG III and ANG IV (391 ± 19 and 274 ± 13 ml·kg-1·min-1, respectively) than for ANG II (107 ± 13 ml·kg-1·min-1). ANG II increased ANG IR by 60 ± 7 pmol/ml, blood pressure by 30%, increased plasma aldosterone markedly (to 345 ± 72 pg/ml), and plasma vasopressin transiently, while reducing glomerular filtration rate (40 ± 2 to 33 ± 2 ml/min), sodium excretion (50 ± 7 to 16 ± 4 μmol/min), and urine flow. Equimolar amounts of ANG III induced similar antinatriuresis (57 ± 8 to 19 ± 3 μmol/min) and aldosterone secretion (to 268 ± 71 pg/ml) at much lower ANG IR increments (∼1/7) without affecting blood pressure, vasopressin, or glomerular filtration rate. The effects of ANG III exhibited complex dose-response relations. ANG IV and ANG-(1-7) were ineffective. It is concluded that 1) plasma clearances of ANG III and ANG IV are higher than those of ANG II; 2) ANG III is more potent than ANG II in eliciting immediate sodium and potassium retention, as well as aldosterone secretion, particularly at low concentrations; and 3) the complexity of the ANG III dose-response relationships provides indirect evidence that several effector mechanisms are involved.